Pancreatic cancer drug daraxonrasib from Revolution Medicines succeeds in trial

Pancreatic cancer drug daraxonrasib from Revolution Medicines succeeds in trial

CNBC general

Key Points:

  • Revolution Medicines ' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemother

Trending Business

Trending Technology

Trending Health